1,470 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Purchased by Cerity Partners LLC

Cerity Partners LLC bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, HoldingsChannel reports. The firm bought 1,470 shares of the medical research company’s stock, valued at approximately $348,000.

A number of other institutional investors have also added to or reduced their stakes in CRL. Czech National Bank grew its position in Charles River Laboratories International by 47.9% during the third quarter. Czech National Bank now owns 8,961 shares of the medical research company’s stock worth $1,756,000 after buying an additional 2,902 shares in the last quarter. Asset Management One Co. Ltd. grew its position in Charles River Laboratories International by 7.7% during the third quarter. Asset Management One Co. Ltd. now owns 20,573 shares of the medical research company’s stock worth $4,032,000 after buying an additional 1,474 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in Charles River Laboratories International by 10.2% during the third quarter. Handelsbanken Fonder AB now owns 8,637 shares of the medical research company’s stock valued at $1,693,000 after purchasing an additional 800 shares in the last quarter. Patriot Financial Group Insurance Agency LLC acquired a new stake in Charles River Laboratories International during the third quarter valued at approximately $209,000. Finally, Mountain Pacific Investment Advisers Inc. ID boosted its holdings in Charles River Laboratories International by 7.1% during the third quarter. Mountain Pacific Investment Advisers Inc. ID now owns 133,181 shares of the medical research company’s stock valued at $26,101,000 after purchasing an additional 8,821 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRL has been the topic of a number of recent research reports. TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Robert W. Baird lifted their price objective on Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. UBS Group lifted their price objective on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Citigroup lifted their price objective on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. Finally, JPMorgan Chase & Co. lifted their price objective on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $253.23.

Insider Buying and Selling

In related news, VP William D. Barbo sold 4,050 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares in the company, valued at approximately $5,685,431.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Victoria L. Creamer sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the transaction, the executive vice president now owns 13,550 shares in the company, valued at approximately $3,437,635. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the sale, the vice president now owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Insiders sold 14,932 shares of company stock worth $3,693,663 in the last quarter. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $229.03 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. The firm has a 50 day moving average of $253.48 and a 200-day moving average of $222.64. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The stock has a market capitalization of $11.80 billion, a P/E ratio of 24.87, a price-to-earnings-growth ratio of 1.88 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $991.25 million. During the same quarter in the previous year, the company posted $2.98 EPS. Charles River Laboratories International’s revenue was down 7.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).